Default company panoramic image

ImpeDx Diagnostics Inc.

ImpeDx is developing a rapid AST platform for positive blood and other clinical samples that will have a significant impact on health care pharmacoeconomics.

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Columbia, MO, USA
  • Currency USD
  • Founded February 2013
  • Employees 2
  • Incorporation Type Not Incorporated
  • Website

Company Summary

ImpeDx has exclusive rights to a rapid method to detect the presence of bacteria or their response to antibiotics in blood culture and other clinical samples. We are developing a novel system for determining the antimicrobial susceptibility (AST) of clinical isolates and samples. Our method significantly reduces time required for AST, thus improving patient outcomes, while reducing healthcare costs & the fostering of antibiotic resistance.


  • Default avatar
    Steve O'Connor

    Dr. O'Connor has been leading technology start-ups since 1992 in a number of sectors, including diagnostics, drug discovery, water treatment, etc. He brings to ImpeDx Diagnostics significant experience in technology development, intellectual property, fundraising, business partnering, and company building.

  • Default avatar
    Kim Mislick

    Dr. Mislick is an Assistant Clinical Professor in the Department of Pathology and Laboratory Medicine at UCLA. She is also the Medical Director of the Northridge Hospital Anatomic and Clinical Pathology Laboratory which performs over 1 million clinical laboratory tests annually. Dr. Mislick is a member of the Northridge Hospital’s Sepsis Task Force. She has served as a consultant to the biotechnology and diagnostics industries for 10 years.

  • Default avatar
    Shramik Sengupta

    Dr. Sengupta, an Associate Professor of Biomedical Engineering at the University of Missouri since 2007, is the lead inventor of the company’s core technology and acts as the part-time CTO. He not only brings detailed technical knowledge of the core technology, but also expertise on adapting the platform for other applications.

  • Dr Swiger has over 30 years of experience in developing technologies for use in applied testing, including healthcare, law enforcement, and environmental applications. He has an extensive network including primary interactions with many of the global top-20 biotech companies. His experience in management and technology development, microchannel fluidics in particular, and sales is an excellent fit for ImpeDx Diagnostics and it's shareholders.

  • Default avatar
    Andy Isakson
    VP, Product Development

    Mr Andy Isakson, EE, is currently a consultant, and will be hired as the VP of Development upon closing the funding round. He has over 35 years of accelerated experience in the areas of electronics, signal processing, plastics, integration, manufacturing, quality, and writing code. Andy will lead the development of prototype systems pursuant to the goals of the current raise.